Verifying a med spa acquirer’s capital: move from buyer interest to transaction evidence

Verify capital by matching the actual transaction’s funding needs with identified equity, debt, approvals, and conditions. Ask who controls each source, what evidence supports availability, and what must happen before closing. A fund size, sponsor biography, or statement of interest is not transaction-specific funding proof. Set proportionate evidence milestones and protect sensitive financial information.

What does the seller need to verify?

The seller needs a reasonable basis to assess whether the buyer can execute the proposal under its stated conditions and timeline. This is different from demanding every private financial document at the first introduction. Match the request to the stage, contemplated structure, and information already being shared.

A capital-evidence milestone is an agreed point in the process when the buyer supplies defined support for a funding assumption. It can concern source identity, authority, availability, lender progress, or conditions. The milestone is useful only if the evidence and consequence of an unresolved gap are clear.

Identify the actual acquiring entity, controlling parties, signing authority, and proposed obligors. A sponsor, fund, platform, acquisition vehicle, and lender are different parties. Ask who is expected to provide cash, who can approve it, and which entity will sign the purchase agreement.

Why begin with a sources-and-uses schedule?

The buyer needs more than the headline price. Uses may include debt payoff, fees, transaction costs, deposits, required working cash, capital spending, and transition resources under the actual structure. Avoid double counting items already included in the purchase mechanics.

List each funding source against these uses: buyer equity, investor equity, acquisition debt, seller debt, retained cash where permitted, or other resources. Show timing and restrictions. A schedule that balances only because a source is labeled other is not a complete explanation.

Ask which assumptions remain estimates and what will refine them. A preliminary schedule can be useful without pretending every fee is final. The seller should understand whether the uncertainty is modest detail or an unfilled source essential to closing.

How do equity resources differ from equity commitments?

A buyer may have wealth, a fund may have commitments, or a platform may have an investor. Those facts do not automatically establish authority to use a specified amount for this acquisition. Ask about investment approval, available capital, restrictions, competing needs, and the actual funding process.

The SEC’s private-placement investor bulletin explains risks and limited information associated with private investments. When a buyer relies on raising investor equity, the seller should distinguish expressions of interest from a completed or binding funding arrangement. The bulletin does not certify the buyer’s offering or available resources.

For an individual buyer, seek appropriately reviewed evidence relevant to the equity contribution without unnecessary disclosure. For a sponsor or group, identify who has authority and whether fundraising remains. Qualified counsel should assess what the documents actually commit and any remaining conditions.

What should be asked about acquisition debt?

SBA’s 7(a) overview describes program uses and the lender’s role. It does not mean a buyer who mentions SBA financing has approval. Ask the actual lender or authorized buyer for the application stage, product, requested amount, key conditions, valuation requirements, equity assumptions, and expected process.

Distinguish a conversation, preliminary indication, term sheet, credit approval, commitment, and completed funding according to the documents involved. These labels are not universal guarantees. Have transaction counsel and the lender explain what remains and whether terms can change.

Reconcile the debt plan with the proposed seller role, rollover, seller note, structure, and ownership. A buyer’s initial spreadsheet can assume financing terms that do not fit the final transaction. Material changes need a refreshed sources-and-uses and executable operating case.

What does a staged evidence request look like?

These are planning examples rather than mandatory legal documents for every transaction. Advisors should tailor the request to the buyer and deal. The useful result is evidence proportional to the seller’s increasing commitment, not an indiscriminate collection of sensitive statements.

How should independent verification be handled?

Confirm identities and contact details through appropriate independent channels. If a buyer authorizes lender or investor confirmation, agree its scope and the information that may be shared. Do not infer permission to contact people from their appearance on a presentation.

Treat screenshots and forwarded letters as items to verify rather than conclusive proof. Ask counsel how to establish authenticity, authority, dates, restrictions, and the relevant balance or commitment. A genuine document can still fail to support the specific conclusion the seller draws from it.

Avoid turning the process into a broad investigation unrelated to the transaction. The question is whether the identified funding plan can execute the deal. Keep requests focused and explain why a particular item matters to the next commitment or disclosure.

What sensitive information should be protected?

The FTC’s Start with Security guide provides practical security principles for access and data handling. Use an appropriately reviewed process for buyer financial evidence, which may contain account information, personal data, or confidential investor details. Broad data-room access is rarely necessary for every item.

Consider redaction, limited reviewer access, confirmation through qualified advisors, and retention controls where appropriate. The seller’s need for confidence does not justify publishing the buyer’s private financial information. Record the conclusion and limitations in a form suited to the decision.

Define who receives the evidence and who can answer questions. A broker’s informal assurance should not be mistaken for an audit or legal guarantee. Be clear about whether evidence was independently reviewed, what it demonstrated, and which conditions remain unresolved.

How do funding conditions affect exclusivity and timing?

Before granting exclusivity, understand the capital tasks that remain, their owners, and the expected evidence dates. Counsel should review the actual exclusivity terms, extension rights, termination provisions, and consequences. The seller can then assess the opportunity cost of waiting.

Ask what happens if credit terms, equity sources, purchase structure, or required uses change. A higher equity requirement or lower loan amount can reopen price and timing. Establish a process for prompt disclosure of material changes rather than discovering the gap near the scheduled closing.

Compare milestones with actual progress. A delay can have a reasonable explanation, but repeated unsubstantiated assurances are different from documented advancement. Preserve the facts and alternatives so the owner can decide whether to continue, revise, or end discussions under the applicable agreement.

What should the final execution memo contain?

Summarize sources and uses, evidence reviewed, authority, dates, conditions, responsible parties, unresolved gaps, and the next decision. Do not describe the deal as funded merely because a spreadsheet balances. The memo should distinguish supported facts from assumptions and expected future steps.

1. Identify the acquiring and funding parties.
2. Build the complete sources-and-uses.
3. Separate resources, authority, and commitments.
4. Define lender and investor conditions.
5. Verify proportionate evidence securely.
6. Update the decision when funding facts change.

Use the seller hub, sponsor and search-fund guide, acquisition-financing guide, and Offer-to-Proceeds Bridge. A credible capital path makes the offer easier to evaluate while keeping approval and funding conditions visible.

What should not be inferred from the review?

Capital evidence does not establish that the buyer is the best operator, that every diligence issue is resolved, or that closing cannot fail. Continue reviewing clinical continuity, legal structure, purchase terms, and the seller’s goals. Funding is a necessary question within a broader decision.

Likewise, a buyer needing financing is not automatically weak. Evaluate the actual resources, process, evidence, and conditions rather than preferring a label such as all cash without understanding its source or restrictions. A transparent conditional proposal can be more assessable than an unsupported assertion of immediate liquidity.

Educational analysis prepared with AI-assisted research for The Med Spa Broker. “Last reviewed” records the source and editorial check date; it does not imply review by an attorney, clinician, or independent appraiser. Read our editorial standards.